. home.aspx



TFF Pharmaceuticals Comments on the Re-formulation of Remdesivir to a Dry Powder Manner for COVID-19 Antiviral Treatment

July 30, 2020 / Business Wire

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today commented on the initial results of research evaluating the development of remdesivir as a dry powder for inhalation by Thin Film Freezing. Findings of the study conducted by a team of researchers at the University of Texas at Austin’s Division of Molecular Pharmaceutics and Drug Delivery, led by Robert O. (Bill) Williams III, the inventor of the TFF technology, was published yesterday as a preprint in bioRxiv.

The research team developed inhaled forms of remdesivir for protecting and treating the respiratory mode of infection, including an amorphous brittle matrix powder made by Thin Film Freezing.

“We are very pleased to report on the efforts of Dr. Williams and his team, who in the span of less than a month and responding to the societal ne...